Hansoh Pharmaceutical Group Co. Ltd. is a pharmaceutical company based in China with a risk rating score of 22.9, indicating a medium risk level. Specializing in research and development, Hansoh Pharmaceutical Group Co. Ltd. offers a diverse range of drugs focusing on CNS diseases, oncology, anti-infectives, and diabetes. Additionally, the company prioritizes metabolic diseases and anti-tumor medications. With a significant revenue stream coming from the sale of pharmaceutical products in Mainland China, Hansoh Pharmaceutical Group Co. Ltd. is a key player in the ESG industry.